Viking Therapeutics Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline
Reuters
Oct 02
<a href="https://laohu8.com/S/VKTX">Viking</a> <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Releases Corporate Presentation Highlighting Advancements in Obesity and Metabolic Disease Drug Pipeline
Viking Therapeutics Inc. has released a corporate presentation outlining updates on its clinical pipeline focused on metabolic and endocrine diseases. The company highlighted progress across several programs, including VK2735, a dual GLP-1/GIP agonist for obesity currently in Phase 3 clinical trials, and an oral formulation of VK2735, which has completed a Phase 2a study. An amylin agonist for obesity is expected to enter clinical development with an IND planned for the fourth quarter of 2025. Additional programs include VK2809, a selective thyroid receptor-β agonist for MASH, which recently completed a successful Phase 2b trial, and VK0214, another thyroid receptor-β agonist for X-ALD, with positive results from a Phase 1b study. You can access the full presentation through the link below. [Full Presentation](https://docs.publicnow.com/1407985E4D5081D9553ABD929FE96930F35D20E6)
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Viking Therapeutics Inc. published the original content used to generate this news brief on October 01, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.